An international review has found that anti‑amyloid drugs developed to treat Alzheimer’s disease provide no clinically ...
A 2026 consumer information overview of how UroFlow presents its Saw Palmetto, Pygeum Africanum, Lycopene, and Tomato Sauce ...
‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ was published in the Cochrane Database of Systematic Reviews at ...
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, ...
Alzheimer’s drugs which pharmaceutical firms hoped could revolutionise dementia treatment ‘likely have no clinically ...
Drugs that are said to slow the progression of Alzheimer’s disease “make no meaningful difference to patients” while ...
Serious doubts have been cast over the efficacy of a new wave of drugs to treat Alzheimer’s disease, with a leading ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...
A 2026 informational overview of ProvaDent's oral probiotic formulation, BioFresh™ enzyme complex, dental sugar hack ...
Drugs aimed at slowing Alzheimer's disease progression "make no meaningful difference to patients" while raising the risk of ...
Clinical interviewing is one of the most important skills physicians develop during their training. It forms the foundation for accurate diagnosis and effective patient care.
6h
Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma
OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results